Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03597581
Title A Study of RGX-202-01 as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Inspirna, Inc.

colorectal adenocarcinoma



Fluorouracil + Irinotecan + Leucovorin + RGX202

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST